Dalpiciclib and endocrine therapy for advanced breast cancer
Part of Cancer clinical trials.
This trial tests a new targeted therapy pill (dalpiciclib) combined with hormone therapy for women with advanced breast cancer that is hormone-receptor positive and HER2-negative. It may help shrink tumors or slow their growth when chemotherapy is not an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman with advanced breast cancer that is hormone-receptor positive (ER or PR positive) and HER2-negative, which cannot be cured by surgery or radiation.
- You have symptoms or signs of cancer spreading to organs like the brain, lungs, liver, or bone marrow, or you cannot tolerate or are not suitable for chemotherapy.
- You are either postmenopausal, or premenopausal and willing to receive a drug to suppress ovarian function, or have had your ovaries removed.
- Your blood counts (white blood cells, platelets, and hemoglobin) are within acceptable levels.
- You have not used a CDK4/6 inhibitor before (like palbociclib, ribociclib, or abemaciclib), and you have had fewer than 3 previous lines of hormone therapy.
- You are not pregnant or breastfeeding, and you are willing to use effective contraception during the study and for 1 year after.
- You do not have active hepatitis B or C, HIV, or a history of certain heart conditions in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Dalpiciclib for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). It aims to see if it can help stop the cancer from growing.
This trial tests a new combination of two drugs (dalpiciclib and an HDAC inhibitor) for people with hormone receptor-positive, HER2-negative advanced breast cancer that has progressed after a CDK4/6 inhibitor. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs (dalpiciclib and toremifene) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It may be an option if you have not had hormone therapy for advanced disease or if your cancer came back more than a year after prior treatments.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
This trial tests a new pill (dalpiciclib) combined with hormone therapy for women with early-stage, hormone receptor positive/HER2-negative breast cancer. The goal is to see if this combination can lower the chance of cancer coming back after surgery.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.